• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

5

CATEGORIES

  • 14
  • 3
  • 1

PRICE

0
0
0
18

PUBLISHED

3
3
7
18

PRODUCT TYPE

18

Search "Alzheimer's Disease – The Evaluation & Management of Dementia 2013" returned 18 results.

PRODUCT TITLE
Alzheimer Disease - New Drugs, Markets and Companies Alzheimer Disease - New Drugs, Markets and Companies - Product Thumbnail Image

Alzheimer Disease - New Drugs, Markets and Companies

Alzheimer's disease remains a challenge in management With nearly 8 million sufferers from this condition in the seven major markets of the world and anticipated increases in the future Considerable...

September 2014
FROM
Neuroprotection - Drugs, Markets and Companies Neuroprotection - Drugs, Markets and Companies - Product Thumbnail Image

Neuroprotection - Drugs, Markets and Companies

This report describes the role of neuroprotection in acute disorders such as stroke and injuries of the nervous system as well as in chronic diseases such as neurodegenerative disorders because many...

September 2014
FROM

Namenda (Alzheimer's Disease) - Forecast and Market Analysis to 2022

Namenda (Alzheimer’s Disease) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Namenda (Alzheimer’s Disease) - Forecast and Market...

July 2013
FROM

Razadyne/Reminyl (Alzheimer's Disease) - Forecast and Market Analysis to 2022

Razadyne/Reminyl (Alzheimer’s Disease) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Razadyne/Reminyl (Alzheimer’s Disease) -...

September 2013
FROM

Aricept (Alzheimer's Disease) - Forecast and Market Analysis to 2022

Aricept (Alzheimer’s Disease) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Aricept (Alzheimer’s Disease) - Forecast and Market...

September 2013
FROM

Namenda XR (Alzheimer's Disease) - Forecast and Market Analysis to 2022

Namenda XR (Alzheimer’s Disease) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Namenda XR (Alzheimer’s Disease) - Forecast and...

July 2013
FROM

Exelon (Alzheimer's Disease) - Forecast and Market Analysis to 2022

Exelon (Alzheimer’s Disease) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Exelon (Alzheimer’s Disease) - Forecast and Market...

September 2013
FROM

TRx0237 (Alzheimer's Disease) - Forecast and Market Analysis to 2022

TRx0237 (Alzheimer’s Disease) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “TRx0237 (Alzheimer’s Disease) - Forecast and Market...

July 2013
FROM

Arimenda (Alzheimer's Disease) - Forecast and Market Analysis to 2022

Arimenda (Alzheimer’s Disease) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Arimenda (Alzheimer’s Disease) - Forecast and Market...

July 2013
FROM

MK-8931(Alzheimer's Disease) - Forecast and Market Analysis to 2022

MK-8931(Alzheimer’s Disease) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “MK-8931(Alzheimer’s Disease) - Forecast and Market...

July 2013
FROM

EVP-6124 (Alzheimer's Disease) - Forecast and Market Analysis to 2022

EVP-6124 (Alzheimer’s Disease) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “EVP-6124 (Alzheimer’s Disease) - Forecast and Market...

July 2013
FROM

Lu AE58054 (Alzheimer's Disease) - Forecast and Market Analysis to 2022

Lu AE58054 (Alzheimer’s Disease) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Lu AE58054 (Alzheimer’s Disease) - Forecast and...

July 2013
FROM

Solanezumab (Alzheimer's Disease) - Forecast and Market Analysis to 2022

Solanezumab (Alzheimer’s Disease) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Solanezumab (Alzheimer’s Disease) - Forecast and...

July 2013
FROM

Gantenerumab (Alzheimer's Disease) - Forecast and Market Analysis to 2022

Gantenerumab (Alzheimer’s Disease) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Gantenerumab (Alzheimer’s Disease) - Forecast...

July 2013
FROM

Crenezumab (Alzheimer's Disease) - Forecast and Market Analysis to 2022

Crenezumab (Alzheimer’s Disease) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Crenezumab (Alzheimer’s Disease) - Forecast and...

July 2013
FROM
Biomarkers - Technologies, Markets and Companies Biomarkers - Technologies, Markets and Companies - Product Thumbnail Image

Biomarkers - Technologies, Markets and Companies

This report follows the broad definition of a biomarker as a characteristic that can be objectively measured and evaluated as an indicator of normal biological or pathogenic processes as well as pharmacological...

September 2014
FROM

Biomarkers: Discovery Techniques and Applications - A Global Market Overview

The potential offered by biomarkers in shaping the outcomes of clinical trials, identifying new drug targets and developing diagnostic assays for detecting diseases early is immense, which has ensued...

November 2013
FROM

Positron Emission Tomography (PET) Markets

The medical imaging segments are poised for a major new phase of growth fueled by the availability of new technology coming out of the computer and digital information technology segment Continuous...

July 2011
FROM
Loading Indicator